Shopping Cart
Remove All
Your shopping cart is currently empty
CGS 15943 is an orally bioavailable non-xanthine antagonist of the Adenosine Receptor. In transfected CHO cells, its Ki values for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $48 | In Stock | In Stock | |
| 10 mg | $79 | In Stock | In Stock | |
| 25 mg | $158 | In Stock | In Stock | |
| 50 mg | $247 | In Stock | In Stock | |
| 100 mg | $372 | In Stock | In Stock | |
| 200 mg | $548 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $53 | In Stock | In Stock |
| Description | CGS 15943 is an orally bioavailable non-xanthine antagonist of the Adenosine Receptor. In transfected CHO cells, its Ki values for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM, respectively. |
| Targets&IC50 | p110δ:8.47 μM, A2A receptor:4.2 nM (ki), A1 receptor:3.5 nM (ki), p110γ:1.1 μM, A3 receptor:51 nM (ki), A2B receptor:16 nM (ki) |
| In vitro | CGS 15943 inhibits the kinase activity of the class IB PI3K isoform p110γ (IC50: 1.1 μM). CGS 15943 shows slight inhibition on p110δ (IC50: 8.47 μM). CGS 15943 (0-20 μM; 24 hours) reduces the phosphorylation of Akt at its residues Ser473 and Thr308 in HLF and Sk-Hep-1 cells. CGS 15943 (0-20 μM; 72 hours) inhibits growth of HLF and SK-Hep-1 cells, as well as HepG2 and PLC-PRF-5 cells[3]. |
| Molecular Weight | 285.69 |
| Formula | C13H8ClN5O |
| Cas No. | 104615-18-1 |
| Smiles | Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1 |
| Relative Density. | 1.72 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 12.22 mg/mL (42.77 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 1 mg/mL (3.5 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.